Recent experimental evidence suggests that acute myeloid leukemias may originate from multiple clones of malignant cells. It is not known how the observed clones may differ with respect to cell properties such as proliferation and self-renewal. There are scarcely any data on how these cell properties change due to chemotherapy and relapse. We propose a new mathematical model to investigate the impact of cell properties on multi-clonal composition of leukemias. Simulation results suggest that fast proliferating and highly self-renewing cells dominate at primary diagnosis while relapse following therapy-induced remission is triggered mostly by highly self-renewing but slowly proliferating cells. Comparison of simulation results to patient data demonstrates that the proposed model is consistent with clinically observed dynamics based on a clonal selection process.
Introduction
Leukemia is a clonal disease of the hematopoietic system leading to extensive expansion of malignant cells that are non functional and cause impairment of blood cell formation. Recent experimental evidence indicates that the malignant cell population might be composed of multiple clones [1] , maintained by cells with stem-like properties [2, 3] . Relapse of the disease after therapy is a common problem of leukemias [1] . Recent gene sequencing studies revealed the genetic association of clones present at diagnosis and at relapse [1, 4] . The significance of clones with multiple mutations potentially driving leukemia on the course of the disease and the impact of the mutations on cellular properties remains unclear [1] . Cells with different mutations might have different growth properties [1] , allowing them to expand more efficiently in different conditions once the competing clones are eliminated by chemotherapy. The latter could explain manifestation of different cell clones at diagnosis and at relapse without a need for additional mutations in between.
Evolution of malignant neoplasms can be interpreted as a selection process of cells with properties that enable them to survive treatment. In this respect the protective role of the niche for primitive leukemia initiating cells or leukemic stem cells (LSC) has been proposed [5, 6, 7] . Chemotherapy significantly alters growth conditions of malignant cells and may, therefore, have a strong impact on the process of cellular selection. Since many classical cytotoxic drugs act specifically at mitotic cells [8] , the intrinsic properties of specific cell clones may play a key role in the selection process.
The aim of this work is to investigate the impact of cell growth properties on the clonal composition of leukemias at diagnosis and at relapse. The significance of intrinsic cell properties on the course of disease has not yet been studied by experiments and the impact of the detected mutations has remained unclear [1] . Mathematical modelling is an appropriate tool to close this gap. Mathematical models permit a systematic study of processes not yet accessible by experimental procedures.
Mathematical approaches have been applied to analyze the regulatory mechanisms controlling the hematopoietic system and its diseases: for reviews see [9, 10, 11, 12] and references therein. In this paper, we introduce two mathematical models of dynamics of leukemia, which are extended versions of models proposed earlier by our group [13, 14, 15] . Two aspects have contributed to the novelty of the models in this work. We have taken recent evidence for the heterogeneity of LSCs into account as well as the impact of chemotherapy on the composition of the LSC population. Many authors, e.g. [16, 17] , have provided evidence for the heterogeneity of LSCs attempting to identify the LSC characteristics, for review see [18] . This heterogeneity is further supported by the results of gene sequencing studies, [1, 19, 20] .
Since the mechanism of interaction between healthy and leukemic cell lines is not well identified, we propose two models. In the first model, we assume that leukemic cells depend on hematopoietic growth factors and interact with hematopoietic cells via competition for these factors. In the second model, we consider autonomous leukemic clones competing with hematopoietic cells for niches in bone marrow which leads to increased cell death due to over-crowding in the bone marrow. The latter model is supported by experimental findings showing signal-independent activation of important cell functions [21, 22, 23] and by an increased cell degradation observed in leukemic patients [24, 25, 26] . Such interactions have not been considered in previous models.
Based on these hypotheses we perform computer simulations, describing time dynamics of the contribution of different clones to the leukemic cell population. Since it is not yet known which mutations are likely to occur and which impact they might have on cell properties, we do not model the mutation process explicitly. We have studied, instead, time evolution of a certain number of leukemic clones already present at the beginning of our observation. The models provide information on the influence of cell properties on the growth dynamics of the different clones in presence or in absence of chemotherapy.
Finally we compare qualitative simulations to clinical data from two patients to show that the proposed models are consistent with clinical observations. We conclude with a discussion of the obtained results. The appendix provides details of mathematical formulation and parametrisation of the proposed models. 
Model assumptions
The models used in this study are based on the models of healthy hematopoiesis proposed and analysed in [13, 27] and extended to account for evolution of a single leukemic clone in [15] .
Based on the classical understanding of hematopoiesis [28] , we assume that the hematopoietic system consists of an ordered sequence of different maturation states, so called compartments, which are sequentially traversed [28] . We treat each compartment as a "well-mixed tank". To describe time evolution of cell populations consisting of huge number of cells we apply ordinary differential equations. The enormous amount of cells forming the hematopoietic system [28, 29] justifies this approach. Evolution of small cell population in the post-therapy period is modeled by assigning random initial cell count according to a Poisson distribution with parameter equal to the average cell count obtained from the deterministic model.
We model time dynamics of one healthy cell lineage and an arbitrary number of leukemic clones. In the description of cell differentiation within each cell line, we choose a two-compartment version of the multicompartment system established in [13] . The model focuses on the maintenance of primitive cells and differentiation from undifferentiated, proliferating cells to differentiated, postmitotic cells. In the case of healthy hematopoiesis, the proliferating cells are hematopoietic stem cells (HSC), hematopoietic progenitor cells (HPC) and precursor cells, the postmitotic cells are mature cells, e.g., white blood cells. The two-compartment architecture is based on a simplified description of the multi-stages differentiation process. Nevertheless as shown in [30] , [31] and [14] models consisting of two compartments capture the dynamics of the multi-compartmental cell population. This allows to reduce the complexity of the differentiation process to focus on mechanisms and effects of competition between different cell lines.
4
Each proliferating cell type is characterised by the following cell properties:
• Proliferation rate, describing how often a cell divides per unit of time.
• Fraction of self-renewal, describing the fraction of daughter cells returning to the compartment occupied by the mother cells that gave rise to them. Based on our earlier work and on compatibility with clinical data [13] , we assume that the fraction of self-renewal of hematopoietic cells is regulated by feedback-signalling.
• Death rate, describing what fraction of cells dies per unit of time. For simplicity, we assume that proliferating cells do not die and postmitotic mature blood cells die at a constant rate.
Production of healthy blood cells is regulated by a negative feedback [32, 33, 34] , mediated by cytokines, such as G-CSF or EPO [34, 28, 35] . If there is a shortage of blood cells of a certain type, the concentration of signalling molecules increases and stimulates expansion of precursor cells. Numerical solutions of the underlying model of hematopoiesis, validated based on the clinical observations after stem cell transplantations [13, 36, 37] , indicate that the regulation of self-renewal is a more efficient mechanism than the regulation of proliferation rates. Similar conclusions were drawn using the models of multistage cell lineages applied to regeneration and maintenance of the mouse olfactory epithelium [38, 39] . Therefore, in the remainder of this paper we assume that the regulatory mechanism is based on the feedback inhibition of self-renewal depending on the level of mature cells.
Model of the healthy cell line
We denote by p c the proliferation rate of mitotic hematopoietic cells and by a c the corresponding fraction of self-renewal. The death rate of mature blood cells is denoted by d c 2 , which is assumed to be positive. We denote the concentration of healthy cell types at time t by c 1 (t), c 2 (t), corresponding to mitotic and mature cells. Based on the notation specified above, the flux to mitosis at time t equals p c (t)c 1 (t). During mitosis the mother cell disappears and gives rise to two daughter cells. The outflux from mitosis at time t equals 2p c (t)c 1 (t), of which the fraction 2a c (t)p c (t)c 1 (t) stays in compartment 1 (process referred to as selfrenewal). The fraction 2 1 − a c 1 (t) p c (t)c 1 (t) moves to compartment 2 (process referred to as differentiation). Since stem cells are the most primitive cells, there exists no influx to the stem cell compartment due to differentiation.
Following [15, 13] , we assume that self-renewal is regulated by a negative feedback. We denote the value of the feedback signal at time t by s(t), which takes values between zero and one. Self-renewal of a certain cell type at time t is assumed to be given as a maximal possible self-renewal of this cell type multiplied by s(t). As described in [15, 13] , we chose s(t) = 1 1+k c c 2 (t) , which can be derived from cytokine kinetics [13] .
We obtain the following system of ordinary differential equations, where a c max corresponds to the maximal possible self-renewal of hematopoietic stem cells.
The two different models proposed in this manuscript differ with respect to the interaction of leukemic and hematopoietic cells. We consider two extreme cases. In Model 1, leukemic cells react to hematopoietic cytokines, in Model 2, leukemic cells are totally independent of hematopoietic cytokines.
Model 1
We assume that leukemic cells depend on the same feedback signal as their normal counterparts. We assume further that the concentration of the feedback signal decreases if mature cell counts or postmitotic leukemic cell (blast) counts increase. This type of feedback models the competition between healthy and leukemic cells for survival signals. In this model the competition takes place by down-regulation of self-renewal. The more differentiated cells exist, the lower self-renewal is. We know from previous studies that low self-renewal is linked to inefficient cell expansion or exhaustion of the stem cell compartment [13] .
We further assume that mature blood cells and leukemic blasts die at constant rates. A schematic representation of the model is given in Fig 1. To write the corresponding equations, we denote the number of leukemic clones by n. As for the hematopoietic cells we consider mitotic and postmitotic cell compartments for each leukemic clone. Let p l i denote the proliferation rate of mitotic cells in leukemic clone i and a l i max the corresponding maximal fraction of self-renewal. By d l i 2 > 0 we denote the clearance rate of postmitotic cells of clone i. Denote by l i 1 (t) the level of mitotic cells of clone i and by l i 2 (t) the level of postmitotic cells at time t. These assumptions result in the following system of ordinary differential equations:
.
Model 2
There is evidence that in some leukemias malignant cells show constitutive activation of certain signalling cascades and thus may become independent of external signals [21, 22, 23] . We consider this scenario in Model 2. In contrast to Model 1, we assume that leukemic cells are independent of hematopoietic cytokines, whereas the hematopoietic cell types depend on the nonlinear feedback described above. Interaction between the healthy and cancer cell lines is modeled through a competition for space resulting in an increased cellular degradation, for example due to overcrowded bone marrow space. This is consistent with the observation of an increase of markers for cell death such as LDH [24, 25, 26] .
We model this effect by introducing a death rate that increases with the number of cells in bone marrow and acts on all cell types residing in bone marrow. For simplicity we suppose that all mitotic and nondividing leukemic cells as well as mitotic hematopoietic cells stay in bone marrow. We assume that the cell mass in bone marrow of healthy persons does not cause any death due to bone marrow crowding. Only if total bone marrow cellularity increases beyond normal, enhanced cell death can be observed.
In Model 1 leukemic cells depend fully on hematopoietic cytokines whereas in Model 2 they are totally independent of environmental signalling. In this sense Model 1 and Model 2 can be understood as the two opposite extremes of a continuum. In reality both mechanisms, competition for environmental signals and direct inhibition or death of hematopoietic cells, may contribute to impaired hematopoietic function [40] . A schematic representation of the models is given in Fig 1. Let d(x) be an increasing function with lim x→∞ d(x) = ∞. This function describes the death rates of bone marrow cells in dependence of bone marrow cell counts x. We assume that under healthy conditions there exists no cell death due to overcrowding. This assumption is in line with bone marrow histology [41] . Therefore, we assume that d(x) = 0 for x <c 1 , wherec 1 is the steady state count of mitotic healthy cells. We assume that the hematopoietic cell lineage is regulated as described above. We obtain the following system of differential equations:
Chemotherapy
We focus on classical cytotoxic therapy acting on fast dividing cells. We introduce chemotherapy into the models by adding a death rate proportional to the proliferation rate. The assumption is motivated by the fact that many of the classical therapeutic agents used for treatment of leukemias act on cells in the phase of division or DNA replication, [42] . Therefore, the rate of induced cell death is proportional to the number of cycling cells.
The linear factor is denoted as k chemo . Under chemotherapy, the equation for mitotic hematopoietic cells in Model 1 takes the form
Similarly, we obtain for mitotic cells of leukemic clone i
Chemotherapy for Model 2 is modeled analogously.
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Simulations
We perform numerical simulations of the models to investigate which leukemic cell properties lead to survival advantage during evolution of leukemogenesis and recurrence under chemotherapy. As mentioned before, the models do not account for new additional mutations. We assume a certain number of leukemic clones to be present at an arbitrary time point and then study their evolution. We assume that in healthy individuals the hematopoietic cells are in a dynamic equilibrium, i.e. production of each cell type equals its clearance and blood cells count is constant over time. Initial conditions for the computer simulations are equilibrium cell counts in the hematopoietic cell lineage and a small cell number for each of the different leukemic clones. We assume that the number of leukemic clones in each patient is 50. This number is arbitrarily chosen. We repeated all described simulations for different numbers of leukemic clones (between 3 and 100) and obtained comparable results.
We assume that primary diagnosis and diagnosis of relapse occur, when healthy blood cell counts are decreased by 50% of their steady state value. We simulate behavior of 50 patients with 50 leukemic clones per patient. The growth properties of the leukemic clones are chosen randomly within certain ranges. The choice of model parameters is described in the Appendix.
We proceed as follows:
(i) We start from healthy equilibrium in the hematopoietic lineage and one mitotic cell per kg of body weight for each leukemic clone. We run simulations until the number of healthy mature blood cells decreases by 50%. We then assess properties of the clones with the highest contribution to the total leukemic cell mass. We take into account all clones with total cell count comprising at least 80% of the total leukemic cell mass. In the following we denote these clones as 'significantly contributing clones'.
(ii) Then, we simulate chemotherapy. For simplification, we consider seven applications of cytotoxic drugs (one per day during seven following days, corresponding to standard inductions). Simulations show that the number of drug applications has no influence on the presented qualitative results.
To account for possible stochastic effects related to a small cell number, we apply a quasi-stochastic approach, in which initial cell densities for the post-therapy period are chosen according to a Poisson distribution such that their expected values are equal to the mean cell density obtained from the deterministic model. We continue simulations until mature blood cell counts decrease by 50% and then assess the cell properties of the clones contributing to relapse.
Remark 2.1 To obtain more insight into possible stochastic effects of small cell number in the periods after therapy, we have compared quasi-stochastic approach with simulations of purely deterministic model based on solutions of ordinary differential equations. In the latter case, when a number of cells in a clone is less than one, we set it to zero. The simulations have shown qualitatively the same results and no significant effects of stochasticity were observed.
Calibration of the hematopoietic part of the model to clinical data and parameters for simulation of two patient examples can be found in the Appendix. Simulations are performed using standard ODE-solvers from the Matlab-software package (Version 7.8, The MathWorks, Inc, Natic, MA) which are based on Runge-Kutta schemes.
Results
Clonality at Diagnosis
We simulate the models to obtain insight into the contribution of different leukemic clones to the total leukemic cell mass. Numerical simulations of the differential equations indicate that at the diagnosis rarely more than 3-4 clones significantly contribute to the total leukemic cell mass. In most cases more than 40-50% of the total leukemic cell mass originates from a single leukemic clone. This finding is identical for both considered models.
Properties of Clones at Diagnosis
Simulations indicate that the clones significantly contributing to the leukemic cell mass have high proliferation rates and high self-renewal potential (high fraction of symmetric self-renewing divisions). Such configuration of parameters leads to an efficient cell expansion. The properties of clones contributing significantly to leukemic cell mass at diagnosis are depicted in Figure 2 . This finding is identical for both considered models.
Clonality at Relapse
The clonality at relapse is comparable to the clonality at diagnosis. Rarely more than three clones significantly contribute to the total leukemic cell mass. This finding is the same for both considered models.
Properties of Clones at Relapse
The properties of the leukemic clones responsible for relapse depend on the efficiency of chemotherapy. We run computer simulations for varied efficiency of chemotherapy, namely different death rates imposed on mitotic cell compartments. In the case of inefficient chemotherapy, i.e. killing rates of mitotic cells being relatively small, the clones present at diagnosis are also responsible for relapse. These clones have high proliferation rates and high self-renewal potential. In the case of more efficient chemotherapy, i.e. killing rates of mitotic cells being higher, the clones responsible for primary presentation differ from the clones responsible for relapse. Compared to the clones leading to primary presentation, the clones responsible for relapse have low proliferation rates but high self-renewal potential. The properties of clones contributing significantly to leukemic cell mass at diagnosis and at relapse are depicted in Figure 3 . Both models lead to similar results.
Treatment of Relapse
If the same treatment strategy as in case of primary treatment is applied to a relapsed patient, remission time is significantly shorter (Fig. 4) . Second relapse is mostly triggered by the same clones as primary relapse. With repeated chemotherapy, clonal composition changes in favor of the clones with minimal proliferation (Clone 5 in Fig. 4) . Repeated chemotherapy can lead to selection of clones that are not competitive in natural environment, i.e. that can be outcompeted by clones sensitive to chemotherapy after cessation of treatment.
Short Term Expansion Efficiency does not Correlate with long Term Self-Maintenance
If leukemic cell behavior depends on hematopoietic cytokines (Model 1), the current signalling environment influences expansion of leukemic clones. In this scenario it is possible that fast proliferating cells with low self-renewal potential dominate the leukemic cell mass during an initial phase. If, with increasing leukemic cell mass, self-renewal becomes down-regulated, e.g. due to occupation of bone marrow niche, eventually the cell clone with the highest affinity to selfrenewal survives, although its proliferation might be slow. An example of time evolution during an early phase is depicted in Fig. 5 .
Late Relapses can Originate from Clones that were Already Present at Diagnosis
Simulations of Model 1 indicate that late relapses, e.g., relapses after more that 3 years, can originate from clones that were already present at diagnosis but did not significantly contribute to the leukemic cell mass at that time. These relapses are triggered by very slow proliferating cells which survive chemotherapy and then slowly grow. At primary diagnosis fast proliferating clones dominate. The slowly proliferating clones are then selected by chemotherapy. This finding is able to explain relapses without additional mutations occurring after primary diagnosis. Thus, temporary risk factor exposure (e.g., chemicals or radiation) can be responsible also for very late relapses and presentations.
Comparison of Simulations to Patient Data
To demonstrate that the proposed modelling framework is consistent with the observed dynamics of leukemia, we perform model calibration to data of two patients. The selected two patients showed different AML-typical mutations. Properties of leukemic cells and their impairment due to chemotherapy cannot be measured directly and the effects of specific mutations on cell dynamics are not well understood. The available data include time periods between induction/consolidation chemotherapy and relapse as well as the percentages of leukemic blasts in the bone marrow at diagnosis, follow-ups and relapse. In addition emergence and subsequent elimination of leukemia driving mutations (FLT3, MLL-PTD) in the bone marrow cells were precisely monitored using molecular biology methods, [43, 44, 45] . We calibrate our models based on these data to verify if and under which assumptions concerning the cell behavior the proposed model is compatible with clinical observations. We assume that each mutation is associated with one leukemic cell clone. The presented calibration can serve as a qualitative 'proof of principle' and lead to hypotheses concerning changes in cell properties induced by the respective mutations. We interpret differences at diagnosis and at relapse as the result of a clonal selection process due to chemotherapy and cell properties.
Simulated time evolution of the leukemic clones in the two considered patients is depicted in Figures 6 and 7 . Simulation results show that bone marrow blast fraction is well described by the model. In Patient 1 FLT3-ITD mutation of a length of 39 bp is detected at diagnosis. This mutation becomes extinct and the relapse is triggered by two different FLT3-ITD mutations (42 bp and 63 bp). This behavior is reproduced in the model simulation: At diagnosis leukemic cell mass is mainly derived from one clone while at relapse two different clones contributed to leukemic cell mass.
In Patient 2 FLT3-ITD mutation and MLL-PTD-mutation were both detected at diagnosis. The MLL-PTD mutation practically did not contribute to relapse. The model is in agreement with patient data: At diagnosis two different clones contribute to leukemic cell mass, one of which becomes extinct and is not detected in the relapse.
Model simulations show that the proposed framework is compatible with clinical observations. Clinical data can be explained by the hypothesis that relapse occurs due to selection of different leukemic clones. Cell clones responsible for relapse may already be present at diagnosis. Clones at relapse have strong self-renewal and slow proliferation, as predicted by the results presented above.
Discussion
The current study has examined the impact of cell properties on clonal evolution of acute myeloid leukemias during the course of disease. We consider two different mathematical models, representing different modes of interactions between normal hematopoietic and leukemic cells. In Model 1 leukemic cells depend on hematopoietic cytokines, niches or other environmental factors. In Model 2 the leukemic cells are independent of these aforementioned determinants and the only interaction between benign and malignant cells is due to a competition for bone marrow space.
Model simulations suggest that clones with high proliferation rate and high self-renewal are favored at primary diagnosis. The results indicate that the number of clones significantly contributing to the leukemic cell mass is relatively small, even if a large number of clones with different leukemia driving mutations might coexist in the bone marrow. This result is in agreement with data from recent gene sequencing studies [1] . It implies that clonal selection due to different growth characteristics is an efficient mechanism to reduce the number of clones contributing to AML cell burden. For example in our simulations they were reduced from 50 to 2-5. Clones not contributing to primary disease manifestations might rest in a slowly proliferating or quiescent state and expand at relapse. Chemotherapy exerts a strong selective pressure on leukemic clones and thus has a considerable impact on the clonal composition during relapse.
In the case of insufficient chemotherapy, the relapse can be triggered by the same clones as the primary disease. In the case of more intensive therapy regimens, relapses are mostly triggered by different clones than primary disease. This has also been concluded from experimental studies [1] . Our models suggest that chemotherapy selects for slowly proliferating clones with high self-renewal property. Depending on efficiency of therapy, it is also possible that clones with high proliferation and high self-renewal potential are responsible for relapse.
In the present study we focus on classical cytotoxic chemotherapy, mostly acting on mitotic cells. This explains selection of slowly proliferating clones. Among the slowly proliferating clones those with high self-renewal potential have a competitive advantage, as shown in earlier studies [13, 14, 15] . High proliferation rates constitute a disadvantageous factor under cytotoxic treatment, since fast proliferating are responsive to even moderately intensive therapy regimens. Relapse due to such clones is only possible if LSCs at the same time have high self-renewal potential, which is an advantageous factor for expansion and survival. Otherwise they would be out-competed by slowly proliferating cells with high self-renewal. Fast proliferating cells with low self-renewal have never been observed at relapse in our simulations. Their emergence at relapse can only be explained by additional mutations acquired after initial treatment. The selection of slowly proliferating cells may explain emergence of resistance in relapses. Applying an identical therapeutic regimen to primary presentation and relapse has, in the absence of new mutations, probably limited effects.
In summary our study suggests that during leukemogenesis high self-renewal and high proliferation are advantageous factors since they lead to fast cell expansion. Under cytotoxic treatment fast proliferation is disadvantageous and selection leads to the emergence of slowly proliferating clones with high selfrenewal. In the case of mild therapy, a disadvantage due to fast proliferation can be compensated by high self-renewal property [13] .
Calibration of the models to patient data show that the proposed framework is compatible with the observed clinical course in the considered two patients. The predicted selection of slowly proliferating cells with high selfrenewal ability is consistent with clinical observations. Comparing simulations of the quasi-stochastic approach to simulations of the fully deterministic model, we observe no significant effects of stochasticity due to small cell numbers left after therapy. Since the selection effect is observed regardless on stochastic effects, we may conclude that it results from the nonlinear and nonlocal dynamics of competing cells.
Our results may have relevance for personalised medicine. Deep sequencing techniques might provide information on the genetic interdependence of the clones present at diagnosis versus relapse [1] . Our model suggests that insufficient therapy might lead to presence of the same clones at diagnosis and relapse. If the clones present at diagnosis and relapse were not identical but related, i.e., they would share common somatic mutations [1] , relapse may be due to a selection process. In this case it is probable that the clones present at relapse show slow proliferation and high self-renewal. One possible implication might be that cell-cycle independent drugs should be employed, such as those used in targeted therapies.
The presented models are based on simplifications, especially the model of chemotherapeutic toxicity. They provide a qualitative proof of principle pointing out that cellular growth properties have a strong impact on clonal evolution of leukemias. The presented results have been observed for wide parameter ranges and different modifications of the model. The observed principles seem thus robust with respect to model assumptions. The proposed model constitutes a framework that explains how leukemic cell properties might change over the course of the disease and explains difficulties in treatment of relapses. Based on the findings of this study it can be concluded that changes in cell properties from primary diagnosis to relapse do not necessarily have to originate from new mutations. They can also be the result of an evolution process related to heterogeneity in growth properties, such as enhanced self-renewal or reduced proliferation.
Model Parameters
For the hematopoietic branch we chose parameters obtained from the calibration in the Section above. For simplicity we assume k c = k l for the feedback mechanism in Model 1. We set the clearance rate of blasts (in absence of effects of overcrowding) to d l i 2 = 0.5, corresponding to a half life between one and two days. Simulation results are qualitatively equivalent for different choices of d l i 2 .
We chose d(x) = d const · max{0, x−x max }. In histological images of healthy adult bone marrow a large part of the bone marrow cavity consists of fat and connective tissue and is free of hematopoietic cells. To take this 'free' space into account, we set x max ≈ 2c 1 , wherec 1 is the steady state count of mitotic healthy cells. For the simulations shown d const was set to 10 −10 . This choice implies that if bone marrow cell counts are three times higher than in steady state, the additional death rate due to overcrowding is of the order of magnitude of mature cell clearance. Even if values of d const are varied within different orders of magnitude, qualitative results remain unchanged.
Chemotherapy is modelled by adding additional death rates to all mitotic cell populations. We apply chemotherapy on seven following days for 2 hours. For simplicity we assume that the additional death rates are constant over this intervals. Different treatment intervals lead to comparable results. Since cytotoxic drugs mainly act on fast dividing cells, we assume that death rates are proportional to proliferation rates of the the respective populations. For population l i 1 the death rate due to chemotherapy is then k chemo · p l i . To simulate different efficiency of chemotherapy, k chemo can be chosen differently. In the depicted simulations k chemo has been set to values between 20 and 30 for less efficient therapy and to values between 35 and 60 for efficient chemotherapy. For different choices similar results are obtained. The higher k chemo , the stronger the selection for high self-renewal and slow proliferation and the lower the probability of relapse. The lower k chemo , the higher the probability that clones contributing to primary presentation are among clones contributing to relapse. For k chemo between 40 and 45, the obtained results are similar to the results obtained in experiments [1] .
The parameters of the leukemic clones are chosen randomly. We assume 24 that cells divide at most twice per day. We only consider clones that are able to out-compete the hematopoietic lineage. In Model 1 this is the case if a l i > a c , in Model 2 this is the case if (2a l i − 1)p l i > (2a c − 1)p c .
Calibration to Patient Examples
Both patients were treated within clinical trials at the University Hospital of Heidelberg after obtaining their written consent. Details on the patients' characteristics and therapeutic regimens can be found in Supplemental Table 1 . Model parameters can be found in Supplemental Tables 2 and 3 . Start and duration of chemo-therapies were simulated as performed during treatment of the patients. Chemotherapy is modeled by increasing death rates for mitotic cell types during the duration of each cycle. For simplicity we did not model kinetics of single chemotherapeutic agents. Instead therapy-induced death rates are assumed to remain constant from the first to the last day of each treatment cycle. The depicted results are based on Model 2. For simplicity we count all leukemic cell types as blasts. 
